Prevention of Recurrent Urinary Tract Infections in Postmenopausal Women

Introduction to Vaginal Estrogen Therapy

The European Association of Urology and the American Medical Association recommend vaginal estrogen as a first-line intervention for preventing recurrent UTIs in postmenopausal women, with strong evidence from 30 randomized controlled trials demonstrating efficacy and an excellent safety profile 1, 2, 3

The European Association of Urology gives vaginal estrogen a "Strong" recommendation for preventing recurrent UTIs in postmenopausal women 2, 3
The American Medical Association provides a "Clear recommendation" based on 30 RCTs and 1 large retrospective observational study 1, 4

Vaginal estrogen works by restoring the vaginal microbiome, reducing vaginal pH, and reversing atrophic changes that predispose to UTIs 1, 4
Estrogen loss during menopause causes loss of protective Lactobacillus species and increases vaginal pH 1, 4

Multiple vaginal estrogen formulations are effective, including vaginal rings, creams, and tablets 1, 4, 5
Available formulations include vaginal rings, vaginal inserts/tablets, and vaginal creams 1, 4

Vaginal estrogen has minimal systemic absorption and an excellent safety profile, even in women with prior estrogen-related malignancies 1, 4
A large prospective cohort study of over 45,000 women found no concerning safety signals regarding stroke, venous thromboembolism, invasive breast cancer, colorectal cancer, or endometrial cancer 1, 4

Initiate vaginal estrogen as the first-line non-antimicrobial intervention, before considering methenamine hippurate or antimicrobial prophylaxis 2, 3, 6
Confirm recurrent UTI diagnosis with urine culture (≥3 UTIs per year or ≥2 in 6 months) 2, 3, 6
Assess for specific risk factors in this age group: urinary incontinence, atrophic vaginitis, cystocele, and high post-void residual volume 2, 3, 6
Start vaginal estrogen as first-line prevention 2, 3, 6
If vaginal estrogen fails or is contraindicated, consider methenamine hippurate (1 g twice daily) as the next antimicrobial-sparing option 1, 4, 6
Reserve continuous antimicrobial prophylaxis only when non-antimicrobial interventions have failed 2, 3, 6